AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8889684
Drug: Cocaine (4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (4, 48, 96 mg/70 kg)
Trial: 8889684
Drug: Drug Recognition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Recognition Examiner (DRE) assessments
Trial: 31050707
Drug: pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab (200 mg every 3 weeks)
Trial: 31050707
Drug: chemotherapy (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy (paclitaxel 175 mg/m2, docetaxel 75 mg/m2, or vinflunine 320 mg/m2, all every 3 weeks)
Trial: 29139592
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g single dose systemic acetaminophen
Trial: 29139592
Drug: Oral opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral opioid consumption
Trial: 25596179
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF, 300 mg/day) monotherapy
Trial: 25596179
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF, 300 mg/day) and entecavir (ETV, 1 mg/day) combination therapy
Trial: 22039171
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) delivered orally (50 mg)
Trial: 22039171
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) delivered to proximal small bowel (PSB) (50 mg)
Trial: 22039171
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) delivered to distal small bowel (DSB) (50 mg)
Trial: 22039171
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) delivered to ascending colon (AC) (50 mg)
Trial: 15043687
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg melatonin for 1 week
Trial: 9497182
Drug: 10% carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbohydrate solution (CHO; 170 +/- 6 g glucose)
Trial: 9497182
Drug: 10% carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbohydrate electrolyte with 5% MCT solution (CHO + MCT; 85 +/- 3 g MCT)
Trial: 9497182
Drug: 5% MCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% MCT solution
Trial: 8803911
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy including hydroxychloroquine, methotrexate, and sulphasalazine
Trial: 6988172
Drug: Feprazone (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feprazone (800 mg daily for 2 days, then 600 mg daily for up to 8 days)
Trial: 6988172
Drug: Phenylbutazone (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone (800 mg daily for 2 days, then 600 mg daily for up to 8 days)
Trial: 25780062
Drug: Exercise plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise plus chemotherapy (cyclophosphamide)
Trial: 16750207
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (40 mg every second day)
Trial: 16750207
Drug: Estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol valerate (2 mg daily)
Trial: 17341565
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of testosterone and estradiol
Trial: 15761754
Drug: High concentration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration of enalaprilat (>50 ng/ml)
Trial: 15761754
Drug: Low concentration
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low concentration of enalaprilat (<10 ng/ml)
Trial: 12082361
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 5 mg/day
Trial: 12082361
Drug: Micronized, oil-suspended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized, oil-suspended progesterone 200 mg/day
Trial: 8701750
Drug: Huperzine-A (Hup)
RxNorm normalized name: huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huperzine-A (Hup) 0.2 mg (4 tablets) orally, twice daily for 8 weeks
Trial: 8701750
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 tablets) orally, twice daily for 8 weeks
Trial: 2140961
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic factor (ANF) infusion (1.95 pmol/min per kg)
Trial: 2140961
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg, administered orally) with physiological saline (placebo)
Trial: 31289040
Drug: Nivolumab and
RxNorm normalized name: nivolumab and relatlimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab and ipilimumab (peri-operative immunotherapy)
Trial: 27988849
Drug: Negative-pressure wound
RxNorm normalized name: Microcyn Negative-Pressure Wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative-pressure wound therapy (NPWT) and antibiotic treatment after surgical debridement
Trial: 9494145
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (60 mg daily)
Trial: 21646599
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg once daily (N=65)
Trial: 21646599
Drug: Metoprolol 95
RxNorm normalized name: metoprolol 95 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 95 mg once daily (N=63)
Trial: 16410677
Drug: Cabergoline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (1 mg/day) + Clarithromycin (400 mg/day) for 6 days
Trial: 16410677
Drug: Cabergoline (stable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (stable doses) + Clarithromycin (400 mg/day) for 6 days
Trial: 16410677
Drug: Cabergoline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (1 mg/day) for 6 days
Trial: 11306204
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated estrogens 0.625 mg/day for 28 days plus MAP 10 mg/day for the last 14 days
Trial: 11306204
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 50 mcg every 7 days for 28 days plus MAP 10 mg/day from 15th to 28th day
Trial: 1907317
Drug: DTP vaccine
RxNorm normalized name: DTP Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP vaccine
Trial: 9272339
Drug: DT vaccine
RxNorm normalized name: Diphtheria Toxoid, Adsorbed/Tetanus Toxoid Intramuscular Suspension [DT VACCINE ADSORBED PEDIATRIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DT vaccine
Trial: 9217687
Drug: Euglycaemia-hypoglycaemia-euglycaemia treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemia-hypoglycaemia-euglycaemia treatment order
Trial: 9217687
Drug: Euglycaemia-placebo(euglycaemia)-euglycaemia treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemia-placebo(euglycaemia)-euglycaemia treatment sequence
Trial: 973963
Drug: Diazepam (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (2.5 mg)
Trial: 973963
Drug: Amylobarbitone sodium
RxNorm normalized name: Amylobarbitone sodium
DrugBank: Amobarbital (DB01351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amylobarbitone sodium (50 mg)
Trial: 977791
Drug: Amylobarbitone sodium
RxNorm normalized name: Amylobarbitone sodium
DrugBank: Amobarbital (DB01351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amylobarbitone sodium (100 mg)
Trial: 973963
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active drugs
Trial: 28830428
Drug: Synergy 1
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synergy 1 (oligofructose-enriched inulin) 10 g daily
Trial: 25253582
Drug: Olmesartan combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan combined with a calcium channel blocker (CCB)
Trial: 25253582
Drug: Olmesartan combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan combined with a diuretic
Trial: 15385015
Drug: Fentanyl (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (30 microg x kg(‐1)) plus morphine (1 mg x kg(‐1))
Trial: 9223734
Drug: Immediate zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate zidovudine (ZVD) therapy
Trial: 3072419
Drug: Ketanserin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (80 mg daily)
Trial: 26526507
Drug: Ribavirin (5‐10mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (5‐10mg/kg daily divided into 2 doses)
Trial: 21982055
Drug: Local steroids
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local steroids
Trial: 18094011
Drug: Pharmacist intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist intervention focused on improving inhalation technique and medication adherence
Trial: 12974594
Drug: Propofol-alfentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-alfentanil infusion
Trial: 12974594
Drug: Boluses of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boluses of fentanyl with a propofol infusion
Trial: 11885172
Drug: Top Performance
RxNorm normalized name: Perform Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Top Performance Group (TPG) implants
Trial: 11885172
Drug: Middle Performance
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle Performance Group (MPG) implants
Trial: 11885172
Drug: Lower Performance
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower Performance Group (LPG) implants
Trial: 11885172
Drug: HA-coated cylinder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-coated cylinder implants
Trial: 11885172
Drug: Commercially pure
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially pure titanium screw implants
Trial: 1349184
Drug: Removal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removal of worms (treatment)
Trial: 31500466
Drug: High-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aspirin treatment
Trial: 22494796
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) treatment
Trial: 16496604
Drug: HA Biocer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA Biocer implants
Trial: 11868925
Drug: Corn syrup
RxNorm normalized name: Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn syrup with synthetic honey flavoring (placebo)
Trial: 10520795
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug (AAD)
Trial: 2656775
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg twice daily)
Trial: 23617687
Drug: Multicomponent pharmaceutical
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Multicomponent pharmaceutical care intervention (patient interview, pharmacotherapy review, execution and follow-up evaluation of a pharmaceutical care plan)
Trial: 23617687
Drug: Multicomponent pharmaceutical
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Multicomponent pharmaceutical care intervention
Trial: 17526934
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/day and 80 mg/day
Trial: 15542205
Drug: HibCRM197 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HibCRM197 vaccine (doses > or =1.25 microg)
Trial: 15542205
Drug: Hib-tetanus vaccine
RxNorm normalized name: tetanus toxoid vaccine, inactivated
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib-tetanus vaccine (doses > or =1.25 microg)
Trial: 11251436
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 10 mg.s-1
Trial: 11251436
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 2 mg.s-1
Trial: 9512842
Drug: Epidural ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ketamine 30 mg before induction of anaesthesia
Trial: 9512842
Drug: Epidural ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ketamine 30 mg 20 min after skin incision
Trial: 7801058
Drug: NSAID cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID cream (DOLGIT cream)
Trial: 3078156
Drug: Individualized antiarrhythmic
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized antiarrhythmic therapy (mexiletine or quinidine)
Trial: 3078156
Drug: Low-dose amiodarone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose amiodarone (200-400 mg/day after a loading phase)
Trial: 10601507
Drug: No antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiarrhythmic therapy
Trial: 23887347
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of thiamine and cobalamin
Trial: 23887347
Drug: Thiamine, Cobalamin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine, Cobalamin, Combination groups
Trial: 19123324
Drug: Hallux-trampling (HT)
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hallux-trampling (HT) plus Yaotongling suppository (YS)
Trial: 19123324
Drug: Hallux-trampling (HT)
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hallux-trampling (HT) plus placebo suppository
Trial: 19123324
Drug: Yaotongling suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yaotongling suppository (YS) plus mock HT
Trial: 17704027
Drug: Purple sweet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purple sweet potato leaves (PSPLs) diet (daily consumption of 200 g PSPLs)
Trial: 12602532
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (477 mg twice daily)
Trial: 12602532
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (954 mg during short study)
Trial: 9236628
Drug: Triple-dose Gd-DTPA
RxNorm normalized name: Gd-EOB-DTPA
DrugBank: Gadoxetic acid (DB08884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-dose Gd-DTPA (0.3 mmol/kg)
Trial: 9236628
Drug: Single-dose Gd-DTPA
RxNorm normalized name: Gd-EOB-DTPA
DrugBank: Gadoxetic acid (DB08884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose Gd-DTPA with MT and short delay
Trial: 9236628
Drug: Triple-dose Gd-DTPA
RxNorm normalized name: Gd-EOB-DTPA
DrugBank: Gadoxetic acid (DB08884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-dose Gd-DTPA with MT and short delay
Trial: 9236628
Drug: MT imaging
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT imaging with long delay following triple-dose Gd-DTPA
Trial: 8398056
Drug: Talcid suspension
RxNorm normalized name: Pulvis Talci
DrugBank: Talc (DB09511)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Talcid suspension (hydrotalcit)
Trial: 21044870
Drug: GAD-alum treatment
RxNorm normalized name: alum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD-alum treatment
Trial: 19069803
Drug: Low-intensity laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity laser therapy
Trial: 29874972
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no laser therapy)
Trial: 26757270
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg qd + promestriene vaginal capsules intravaginally (Group A)
Trial: 26757270
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg qd (Group B)
Trial: 24962003
Drug: 120 mmol
RxNorm normalized name: dibasic potassium phosphate 120 MMOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mmol l(‐1) Na(+)
Trial: 24962003
Drug: 180 mmol
RxNorm normalized name: PEG-180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mmol l(‐1) Na(+)
Trial: 24962003
Drug: 60 mmol
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mmol l(‐1) Na(+)
Trial: 8699333
Drug: Granulated tablet
RxNorm normalized name: Granule Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulated tablet formulation of nadolol (80 mg) - single dose
Trial: 8699333
Drug: Compressed tablet
RxNorm normalized name: Ulva compressa extract
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compressed tablet formulation of nadolol (80 mg) - single dose
Trial: 8699333
Drug: Granulated tablet
RxNorm normalized name: Granule Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulated tablet formulation of nadolol (80 mg) - multiple doses (once daily for 7 days)
Trial: 8699333
Drug: Compressed tablet
RxNorm normalized name: Ulva compressa extract
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compressed tablet formulation of nadolol (80 mg) - multiple doses (once daily for 7 days)
Trial: 1379056
Drug: Ephedrine 17.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 17.5 mg and 3% Dextran 70 7.5 ml kg‐1 before delivery (group A)
Trial: 1379056
Drug: Volume loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume loading with Dextran 15 ml kg‐1 without infusion of ephedrine (group B)
Trial: 29938898
Drug: Venlafaxine (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (37.5 mg)
Trial: 21910547
Drug: Morning administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning administration of TOVA
Trial: 21910547
Drug: Afternoon administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Afternoon administration of TOVA
Trial: 20974316
Drug: Dexlansoprazole 30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole 30, 60, and 90 mg once daily
Trial: 20974316
Drug: Dexlansoprazole 30
RxNorm normalized name: dexlansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole 30 or 60 mg once daily
Trial: 20974316
Drug: Dexlansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole 60 and 90 mg once daily
Trial: 18726104
Drug: Prophylactic intravenous
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic intravenous gentamicin, administered 30 min before surgery.
Trial: 18726104
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prophylactic antibiotics).
Trial: 15652875
Drug: Repetitive TMS
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Repetitive TMS (rTMS) at 5 Hz, 20 sessions (5 sessions per week) of 120% of motor threshold and 1250 pulses per session, concomitantly taking amitriptyline (mean dose 110 mg/d)
Trial: 2719366
Drug: Actidose‐Aqua 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actidose‐Aqua 25 g
Trial: 2719366
Drug: Super Char
RxNorm normalized name: octinoxate 7.5 mL in 100 mL / titanium dioxide 1 mL in 100 mL TOPICAL CREAM [HAVE A NICE DAY SUPER CHARGED SPF 15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Super Char 25 g
Trial: 53428
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B immune globulin (H.B.I.G.)
Trial: 53428
Drug: Immune serum
RxNorm normalized name: IMMUNE SERUMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune serum globulin (I.S.G.)